Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population
Study Details
Study Description
Brief Summary
Background:
The influenza (flu) virus infects millions around the world every year. Children are at increased risk of complications from the flu. The flu vaccine protects against influenza, but the vaccine can be improved. Researchers want to learn more about children s mucosal and systemic immunity after flu vaccination. This could help to develop more effective flu vaccines in the future.
Objective:
To learn what happens in kids immune systems after receiving a flu vaccine.
Eligibility:
Children ages 2-17 who have received a flu vaccine in the past and plan to get the current seasonal flu vaccine given by injection.
Design:
All study visits will take place at home and communication with the study team will be done via phone or videoconference.
Participants will review medical history and flu vaccination history with the study team.
Participants will get the flu vaccine at their local doctor s office or pharmacy. They will not be given the vaccine in this study.
Participants will complete an electronic survey to give details about the date and type of flu vaccine received.
Participants will collect nasal and fingerstick samples at home. They will collect 4 nasal samples and 3 fingerstick samples over 6 months: once before they get the flu vaccine and 2-3 times after they get the vaccine. They will use collection kits that include instructions, sample collection supplies, and shipping materials. They will ship all samples back to NIH with all costs covered by NIH.
Participation will last for 6 months.
Compensation is provided.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Title:
Natural History of Systemic and Nasal Mucosal Immunity after Influenza Vaccination in a Pediatric Population
Study Description:
While adults are heavily represented in influenza vaccine studies, there are limited studies in the pediatric population. This study will characterize the changes in nasal and systemic immunity after influenza vaccination in a pediatric population.
Objectives:
Primary Objectives:
Characterize nasal mucosal humoral immune response pre and post influenza vaccination
Characterize systemic humoral immune response pre and post influenza vaccination
Secondary Objectives:
Describe the trend of nasal mucosal mucosal and serum humoral immune response over time after vaccination
Endpoints:
Primary Endpoints:
-
Baseline and post-vaccination mucosal anti-influenza antibodies from nasal samples as measured by:
-
Anti-hemagglutination (HA) head antibody quantitative enzyme-linked immunosorbent assay (ELISA) immunoglobulins (Ig) (IgA, IgG)
-
Anti-HA stalk antibody quantitative ELISA (IgA, IgG)
-
Anti-neuraminidase (NA) antibody quantitative ELISA (IgA, IgG)
-
Baseline and post-vaccination systemic anti-influenza antibodies as measured by:
-
Anti-HA head antibody quantitative ELISA (IgM, IgG, IgA)
-
Anti-HA stalk antibody quantitative ELISA (IgM, IgG, IgA)
-
Anti-NA antibody quantitative ELISA (IgM, IgG, IgA)
Secondary Endpoints:
Multiple timepoint measurements of mucosal anti-influenza antibodies from nasal samples as measured by:
Anti-HA head antibody quantitative ELISA (IgA, IgG)
Anti-HA stalk antibody quantitative ELISA (IgA, IgG)
Anti-NA antibody quantitative ELISA (IgA, IgG)
Multiple timepoint measurements of systemic anti-influenza antibodies as measured by:
Anti-HA head antibody quantitative ELISA (IgM, IgG, IgA)
Anti-HA stalk antibody quantitative ELISA (IgM, IgG, IgA)
Anti-NA antibody quantitative ELISA (IgM, IgG, IgA)
Study Population:
Children who are >= 2 years and < 18 years of age (N = 51; accrual ceiling = 100). Participants will be enrolled by age group: 2 - 6 years old, 7 - 11 years old and 12 - 17 years old with a goal enrollment of 17 per group.
Description of Sites/Facilities Enrolling Participants:
Participants will be enrolled by telephone or videoconference, and sample collections will be done in participant homes. Recruitment will be from community pediatric clinics and self- or family referral.
Study Duration:
2 years
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 12-17 years of age 12-17 years of age |
|
| 2-6 years of age 2-6 years of age |
|
| 7-11 years of age 7-11 years of age |
Outcome Measures
Primary Outcome Measures
- Baseline and post-vaccination (6 weeks) systemic anti-influenza antibodies as measured by: 1. Anti-HA head antibody quantitative ELISA IgM, IgG, IgA 2. Anti-HA stalk antibody quantitative ELISA IgM, IgG, IgA 3. Anti-NA antibody quantitative ELIS... [6 weeks]
Systemic anti-influenza antibodies
- Baseline and post-vaccination (6 weeks) mucosal anti-influenza antibodies from nasal samples as measured by: 1. Anti-HA head antibody quantitative ELISA IgA, IgG 2. Anti-HA stalk antibody quantitative ELISA IgA IgG 3. Anti-NA antibody quantitati... [6 weeks]
Mucosal anti-influenza antibodies
Secondary Outcome Measures
- post-vaccination systemic anti-influenza antibodies [24 weeks]
Systemic anti-influenza antibodies
- post-vaccination mucosal anti-influenza antibodies [24 weeks]
Mucosal anti-influenza antibodies
Eligibility Criteria
Criteria
- INCLUSION CRITERIA:
In order to be eligible to enroll in this study, an individual must meet all of the following criteria:
-
= 2 years of age and < 18 years of age at the time of enrollment.
-
Completed a previous influenza series in the past and therefore requires only one seasonal influenza vaccine every year.
-
Planning to receive the current seasonal inactivated influenza vaccine given by injection.
-
Parent or guardian willing and able to provide verbal consent.
-
Willing and able to undergo home blood micro-sampling and nasal sampling.
-
Willing to have samples stored for future research.
-
Parent/guardian able to proficiently speak, read, and write English.
EXCLUSION CRITERIA:
Any individual who meets any of the following criteria will be excluded from participation in this study:
-
Already received the current season s influenza vaccine.
-
Planning to receive the current seasonal live attenuated influenza vaccine (LAIV).
-
Self-reported pregnancy or breastfeeding.
-
Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
- Principal Investigator: Alison Han, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10000488
- 000488-I